Complications of Oral Anticoagulant Therapy: Bleeding and Nonbleeding, Rates and Risk Factors

Elaine M. Hylek

doi:10.1055/s-2003-44463

Seminars in Vascular Medicine, Table of Contents

Semin Vasc Med 2003; 03(3): 271-278
DOI: 10.1055/s-2003-44463

Complications of Oral Anticoagulant Therapy: Bleeding and Nonbleeding, Rates and Risk Factors

Elaine M. Hylek

Harvard Medical School, General Medicine Division, Clinical Epidemiology Unit, Massachusetts General Hospital, Boston, MA

Abstract

ABSTRACT

Oral anticoagulant therapy is very effective in preventing thromboembolism. Its major complication is hemorrhage. The rate of intracranial bleeding from randomized trials and observational studies ranges from 0.1 to 0.9% per year and largely depends on the International Normalized Ratio (INR) target range. Risk factors for this often-fatal complication include INR intensity, older age, cerebrovascular disease, and hypertension. Recent insights into the pathogenesis of intracerebral hemorrhage have focused on underlying arterial vasculopathies that predispose to bleeding, particularly in the elderly. The rate of major extracranial hemorrhage on oral anticoagulant therapy ranges from 0.4 to 2% per year. Different definitions of major hemorrhage, INR target ranges, age distribution, burden of comorbid illness, and type of coumarin challenge comparability of studies. Additional risk factors for major hemorrhage include history of gastrointestinal bleeding, concurrent use of antiplatelet or nonsteroidal anti-inflammatory drugs, genetic differences in warfarin metabolism, INR variability, type of coumarin, comorbid illnesses, and duration of oral anticoagulant therapy.

KEYWORDS

Oral anticoagulant - warfarin - hemorrhage - intracranial hemorrhage

Full Text

References

REFERENCES

1 Graafsma Y P, Prins M H, Lensing W A. et al . Bleeding classification in clinical trials: observer variability and clinical relevance. Thromb Haemost . 1997; 78 1189-1192
2 Landefeld C S, Anderson P A, Goodnough L T. et al . The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol . 1989; 42 711-718
3 Beyth R J, Quinn L M, Landefeld C S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med . 1998; 105 91-99
4 Koopman M MW, Prandoni P, Piovella F. et al . Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med . 1996; 334 682-687
5 Go A S, Hylek E M, Phillips K A. et al . Prevalence of diagnosed atrial fibrillation in adults-national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA . 2001; 285 2370-2375
6 Franke C L, De Jonge J, van Swieten C J. et al . Intracerebral hematomas during anticoagulant treatment. Stroke . 1990; 21 726-730
7 Wintzen A R, de Jonge H, Loeliger E A. et al . The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol . 1984; 16 533-558
8 Forsting M, Mattle H P, Huber P. Anticoagulation-related intracerebral hemorrhage. Cerebrovasc Dis . 1991; 1 97-102
9 Fogelholm R, Eskola K, Kiminkinen T. et al . Anticoagulant treatment as a risk factor for primary intracerebral hemorrhage. J Neurol Neurosurg Psych . 1992; 55 1121-1124
10 Hylek E M, Singer D E. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med . 1994; 120 897-902
11 Rosand J, Hylek E M, O'Donnell H C. et al . Warfarin-associated hemorrhage and cerebral amyloid angiopathy. Neurology . 2000; 55 947-951
12 Radberg J A, Olsson J E, Radberg C T. Prognostic parameters in spontaneous intracerebral hematomas with special reference to anticoagulant treatment. Stroke . 1991; 22 571-576
13 Stroke Prevention in Reversible Ischemia Trial Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol . 1997; 42 857-865
14 Gorter J W. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. Neurology . 1999; 53 1319-1327
15 Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med . 1996; 156 409-416
16 Landefeld C S, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med . 1989; 87 144-152
17 Hart R G, Boop B S, Anderson D C. Oral anticoagulants and intracranial hemorrhage: facts and hypotheses. Stroke . 1995; 26 1471-1477
18 Manolio T A, Kronmal R A, Burke G L. et al . Magnetic resonance abnormalities and cerebrovascular disease in older adults: the Cardiovascular Health Study. Stroke . 1994; 25 318-327
19 Smith E E, Rosand J, Knudsen K A. et al . Leukoaraiosis is associated with warfarin-related hemorrhage following ischemic stroke. Neurology . 2002; 59 193-197
20 van Swieten C J, Hijdra A, Koudstaal P J. et al . Grading white matter lesions on CT and MRI: a simple scale. J Neurol Neurosurg Psych . 1990; 53 1080-1083
21 Okazaki H, Reagan T J, Campbell R J. Clinicopathologic studies of primary cerebral amyloid angiopathy. Mayo Clin Proc . 1979; 54 22-31
22 Vinters H V. Cerebral amyloid angiopathy. A critical review. Stroke . 1987; 18 311-324
23 Greenberg S M, O'Donnell H C, Schaefer P W. et al . MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology . 1999; 53 1135-1138
24 Roob G, Schmidt R, Kapellar P. et al . MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology . 1999; 52 991-994
25 Albers G W, Dalen J E, Laupacis A. et al . Antithrombotic therapy in atrial fibrillation. Chest . 2001; 119(suppl) 194S-206S
26 Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med . 1994; 154 1449-1457
27 Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet . 1994; 1 499-503
28 Smith P, Arneson H, Holme I. The effect of warfarin on mortality and re-infarction after myocardial infarction. N Engl J Med . 1990; 323 147-152
29 Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet . 1996; 348 633-638
30 van der Meer J M F, Rosendaal F R, Vandenbroucke J P. et al . Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med . 1993; 153 1557-1562
31 Fihn S D, McDonell M, Martin D. et al . Risk factors for complications of chronic anticoagulation. A multi-center study. Ann Intern Med . 1993; 118 511-520
32 Palareti G, Leali N, Coccheri S. et al . Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet . 1996; 348 423-428
33 Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice. Arch Intern Med . 2001; 161 1443-1447
34 Wells P S, Holbrook A M, Crowther N R. et al . Interactions of warfarin with drugs and food. Ann Intern Med . 1994; 121 676-683
35 Hylek E M, Heiman H, Skates S J. et al . Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA . 1998; 279 657-662
36 Hylek E M, Chang Y, Skates S J. et al . Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med . 2000; 160 1612-1617
37 Fihn S D, Callahan C M, Martin D C. et al . The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med . 1996; 124 970-979
38 Gurwitz J H, Avorn J, Ross-Degnan D. et al . Aging and the anticoagulant response to warfarin. Ann Intern Med . 1992; 116 901-904
39 James A H, Britt R P, Raskino C L. et al . Factors affecting the maintenance dose of warfarin. J Clin Pathol . 1992; 45 704-706
40 Wynne H A, Kamali F, Edwards C. et al . Effect of ageing upon warfarin dose requirements: a longitudinal study. Age Ageing . 1996; 25 429-432
41 Hylek E M. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clin Geriatric Med . 2001; 17 1-13
42 Hylek E M, Regan S, Go A S. et al . Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med . 2001; 135 393-400
43 Aithal G P, Day C P, Kesteven P JL. et al . Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet . 1999; 353 717-719
44 Higashi M K, Veenstra D L, Kondo L M. et al . Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA . 2002; 287 1690-1698
45 Pettiti D B, Strom B L, Melmon K L. Duration of warfarin anticoagulation therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med . 1986; 81 255-259
46 Harrison L, Johnston M, Massicotte M P. et al . Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med . 1997; 126 133-136
47 Fennerty A, Dolben J, Thomas P. et al . Flexible induction dose regimen for warfarin and prediction of maintenance dose. Br Med J . 1984; 288 1268-1270
48 Roberts G W, Druskeit T, Jorgensen L E. et al . Comparison of an age adjusted warfarin loading protocol with empirical dosing and Fennerty's protocol. Aust NZ J Med . 1999; 29 731-736
49 Gedge J, Orme S, Hampton K K. et al . A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing . 2000; 29 31-34
50 Choudari C P, Rajgopal C, Palmer K R. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut . 1994; 35 464-466
51 Griffin M R, Piper J M, Daugherty J R. et al . Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med . 1991; 114 257-263
52 Gabriel S E, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. Ann Intern Med . 1991; 115 787-796
53 Shorr R I, Ray W A, Daugherty J R. et al . Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med . 1993; 153 1665-1670
54 Physicians' Desk Reference. Montvale, NJ: Medical Economics; 2001;2051,2484
55 Tincani E, Bertoni G, Silingardi M. et al . Helicobacter pylori, a frequent and potentially dangerous guest in the gastroduodenal mucosa of anticoagulated patients. Am J Med . 2000; 108 165-167
56 Saour J N, Sieck J O, Mamo L AR. et al . Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med . 1990; 322 428-432
57 Hull R, Hirsh J, Jay R. et al . Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med . 1982; 307 1676-1681
58 Altman R, Rouvier J, Gurfinkel E. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg . 1991; 101 427-431
59 Turpie A GG, Gunstensen J, Hirsh J. et al . Randomized comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet . 1988; 1 1242-1245
60 Chiquette E, Amato M G, Bussey H I. Comparison of an anticoagulation clinic and usual medical care: anticoagulation control, patient outcomes, and health care costs. Arch Intern Med . 1998; 158 1641-1647
61 Wilt V M, Gums J G, Ahmed O I. et al . Pharmacy operated anticoagulation service: improved outcomes in patients on warfarin. Pharmacotherapy . 1995; 15 732-779
62 Bauer K A. Coumarin-induced skin necrosis. Arch Dermatol . 1993; 129 766-768
63 Devereaux P J, Anderson D R, Gardner M J. et al . Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study. Br Med J . 2001; 323 1-7